Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.440 USD | +3.83% |
|
+8.44% | +6.09% |
Jan. 13 | Rein Therapeutics Inc.(NasdaqCM:RNTX) added to NASDAQ Composite Index | CI |
Jan. 13 | Aileron Therapeutics, Inc. will Change its Ticker to RNTX from ALRN | CI |
Capitalization | 52.86M 50.45M 47.61M 41.91M 74.97M 4.59B 83.02M 566M 210M 1.92B 198M 194M 8B | P/E ratio 2024 * |
-1.82x | P/E ratio 2025 * | -1.72x |
---|---|---|---|---|---|
Enterprise value | 52.86M 50.45M 47.61M 41.91M 74.97M 4.59B 83.02M 566M 210M 1.92B 198M 194M 8B | EV / Sales 2024 * |
-
| EV / Sales 2025 * | - |
Free-Float |
99.35% | Yield 2024 * |
-
| Yield 2025 * | - |
Last Transcript: Rein Therapeutics Inc.
1 day | +3.83% | ||
1 week | +8.44% | ||
Current month | +23.86% | ||
1 month | +22.00% | ||
3 months | -14.98% | ||
6 months | +29.10% | ||
Current year | +6.09% |







Manager | Title | Age | Since |
---|---|---|---|
Brian Windsor
CEO | Chief Executive Officer | 59 | 2024-03-10 |
Director of Finance/CFO | 63 | 2024-05-15 | |
David Annis
CTO | Chief Tech/Sci/R&D Officer | 52 | 2018-11-04 |
Director | Title | Age | Since |
---|---|---|---|
Reinhard Ambros
BRD | Director/Board Member | 69 | 2013-05-31 |
Director/Board Member | 55 | 2018-09-05 | |
Chairman | 70 | 2023-10-30 |
Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
---|---|---|---|---|---|---|
+3.83% | +8.44% | -47.97% | -71.12% | 52.86M | ||
-0.77% | -2.33% | +8.72% | +97.19% | 118B | ||
-0.10% | -2.43% | -28.95% | +7.48% | 72.09B | ||
+1.12% | -2.75% | +70.11% | +143.60% | 39.13B | ||
-2.40% | +3.96% | +30.72% | -23.85% | 28.73B | ||
+2.38% | +5.09% | +55.74% | +12.51% | 24.63B | ||
+4.77% | +6.35% | +17.32% | -36.67% | 24.62B | ||
-2.06% | +4.24% | +321.50% | +968.50% | 15.76B | ||
+0.81% | +1.52% | +168.76% | +237.20% | 14.19B | ||
+0.37% | +8.99% | -19.60% | -31.36% | 13.48B | ||
Average | +0.80% | +3.81% | +57.63% | +130.35% | 35.06B | |
Weighted average by Cap. | +0.11% | -0.50% | +32.98% | +98.52% |
2024 * | 2025 * | |
---|---|---|
Net sales | - | - |
Net income | -24.5M -23.38M -22.07M -19.42M -34.74M -2.13B -38.48M -262M -97.18M -888M -91.82M -90M -3.71B | -36.39M -34.73M -32.78M -28.85M -51.61M -3.16B -57.16M -389M -144M -1.32B -136M -134M -5.51B |
Net Debt | - | - |
Date | Price | Change | Volume |
---|---|---|---|
25-02-14 | 2.440 $ | +3.83% | 35,120 |
25-02-13 | 2.350 $ | +2.17% | 23,110 |
25-02-12 | 2.300 $ | +7.98% | 31,287 |
25-02-11 | 2.130 $ | -5.33% | 32,196 |
Delayed Quote Nasdaq, February 14, 2025 at 04:00 pm EST
More quotes
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- RNTX Stock